Company Overview of NeuroPhage Pharmaceuticals, Inc.
NeuroPhage Pharmaceuticals, Inc., a biotechnology company, develops disaggregating misfolded proteins for the treatment and prevention of chronic neurodegenerative diseases. It also develops therapeutics for the treatment of Alzheimer‘s, Parkinson‘s, and other degenerative diseases. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
222 Third Street
Cambridge, MA 02142
Founded in 2006
Key Executives for NeuroPhage Pharmaceuticals, Inc.
Co-Founder and Chief Executive Officer
Chairman of Scientific Advisory Board
Scientific Founder and Member of Scientific Advisory Board
Senior Vice President of Preclinical Research and Development
Compensation as of Fiscal Year 2014.
NeuroPhage Pharmaceuticals, Inc. Key Developments
NeuroPhage Pharmaceuticals, Inc. Presents at Biotech Showcase 2014, Jan-14-2014 08:00 AM
Dec 23 13
NeuroPhage Pharmaceuticals, Inc. Presents at Biotech Showcase 2014, Jan-14-2014 08:00 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States. Speakers: Jonathan Solomon, Co-Founder, Chief Executive Officer, President and Director.
NeuroPhage Pharmaceuticals, Inc. Wins Second Grant from Michael J. Fox Foundation for Parkinson's Disease Research
Dec 19 13
NeuroPhage Pharmaceuticals, Inc. announced that it has been awarded an $822,000 grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) for its second-generation drug candidate, NPT088, based on NeuroPhage's GAIM (general amyloid interaction motif) platform, which simultaneously targets multiple misfolded proteins central to many neurodegenerative diseases. In particular, the MJFF grant will be applied to research the effect of NPT088 on alpha-synuclein deposits in the brain, a pathological hallmark of Parkinson's disease (PD). This is NeuroPhage's second grant from MJFF applied to the GAIM platform. The proceeds of the new MJFF grant will be used to test the effect of NPT088 on alpha-synuclein accumulation in the brain in a preclinical model of PD. The preclinical study will be conducted in collaboration with Dr. Eliezer Masliah at the University of California, San Diego. NeuroPhage previously demonstrated that a single treatment of NPT001, a first-generation GAIM molecule, produced significant reductions in neuropathology along with improved motor performance in preclinical PD models. NPT088 is in development for the treatment of conditions characterized by multiple misfolded proteins, with initial focus on PD and Alzheimer's disease (AD). Multiple misfolded proteins are often present in such diseases and can increase disease severity and accelerate disease progression.
NeuroPhage Pharmaceuticals, Inc. Names John F. Dee as Chairman and Kenneth A. Buckfire as Director to its Board
May 6 13
NeuroPhage Pharmaceuticals, Inc. announced that current Director John F. Dee has been named Chairman of the Board and Kenneth A. Buckfire has joined as a Director. In connection with the financing, NeuroPhage announced that John F. Dee has been named Chairman and Kenneth A. Buckfire has joined the Board as a Director. Mr. Dee brings a wealth of industry experience as the former CEO of several successful neuroscience-focused biotechnology companies that were acquired by major pharmaceutical firms. Mr. Buckfire brings extensive strategic and financial experience as Vice Chairman of Stifel Investment Banking and President of Miller Buckfire & Company, a Stifel Company.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 21, 2014